Clinical efficacy of integrated treatment (Yiqiyangxue compound and Western medicine) on RITP and the changes of platelet membrane glycoprotein CD41 and CD61
Abstract：【Objective】 To investigate the clinical efficacy of integrated traditional Chinese and Western medicine in the treatment of refractory immune thrombocytopenia (RITP) and the level changes of platelet membrane glycoprotein CD41 and CD61 before and after treatment.【Methods】 Seventy-eight cases of RITP in our hospital from May 2010 to December 2014, were randomly divided into control group and observation group, 39 cases in each group.The control group was given prednisone tablets, and the observation group was given the combined treatment prednisone tablets + yiqiyangxue decoction. After 6 months of treatment, the clinical effects of the two groups and the changes of platelet count, platelet membrane glycoprotein CD41, CD61 and T cell subsets were compared before and after treatment. 【Results】 After treatment, the total efficiency of the observation group was significantly higher than the control group, the statistical difference was significant (χ2=20.146,P<0.05); After treatment, PLT, PCT, CD41, CD61 of the two groups were significantly higher than those before treatment (P<0.05), and the increase rate of the observation group was higher than that of the control group (P<0.05); After treatment, CD3+、CD4+、CD4+/ CD8+ of the two groups were significantly higher than those before treatment, CD8+ was significantly lower than that before treatment (P<0.05), the change rate of the observation group was greater than that of the control group (P<0.05); Compared with the control group, the side effects of glucocorticoid in the observation group were significantly improved (P<0.05).【Conclusion】 The clinical efficacy of combination of traditional Chinese and Western medicine for treatment of RITP is better than simple western medicine treatment. The integrated therapy can improve the cellular immune function of patients and reduce the side effects of glucocorticoid, and improve the level of platelet membrane glycoprotein CD41 and CD61.
冀晓红;李草旎;高谒萍;张杰. 益气养血方联合西医治疗难治性血小板减少症疗效及对血小板膜糖蛋白CD41、CD61水平影响[J]. 医学临床研究, 2016, 33(10): 1969-1972.
JI Xiao-hong, LI Cao-ni, GAO Ye-ping,et al. Clinical efficacy of integrated treatment (Yiqiyangxue compound and Western medicine) on RITP and the changes of platelet membrane glycoprotein CD41 and CD61. JOURNAL OF CLINICAL RESEARCH, 2016, 33(10): 1969-1972.
[1] Mahévas M, Gerfaud-Valentin M, Moulis G,et al. Characteristics, outcome and response to therapy of multirefractory chronic immune thrombocytopenia[J].Blood,2016,128(12):1625-1630. [2] Rashidi A, Blinder MA. Combination therapy in relapsed or refractory chronicimmune thrombocytopenia: a case report and literature review[J].J Clin Pharm Ther,2016,41(5):453-458. [3] Sanz M, Vicente García V, Fernández A, et al. Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia[J].Med Clin (Barc),2012,138(6):261.e1-261.e17. [4] Boyers D, Jia X, Crowther M, et al. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP)[J].Health Technol Assess,2011,15(Suppl 1):23-32. [5] 马静瑶,陈振萍,吴润晖,等.血小板特异性抗体与ITP发病、临床特点、治疗及预后效果的关系[J].中国实验血液学杂志,2014,22(6):1771-1774. [6] 刘世研.难治性免疫性血小板减少性症的中医治疗进展[J].中医临床研究,2015,7(28):141-142. [7] 中华医学会血液分会血栓与止血学组.成人原发免疫性血小板减少症诊治的中国专家共识(修订版)[J].中华血液学杂志,2011,32(3):214-216. [8] 张之南. 血液病诊断及疗效标准[M].天津:天津科学技术出版社,2007:173. [9] 李小倩.难治性特发性血小板减少性紫癜的治疗现状[J].实用医学杂志,2012,28(4):664-666. [10] 潘月芬,方遒,吴霞雯,等.免疫抑制剂联合应用治疗慢性难治性ITP效果分析[J].实用药物与临床,2013,16(6):487-489. [11] 马鸿雁,王一浩,孙玲,等.难治性原发免疫性血小板减少症利妥昔单抗治疗无效的原因初探[J].中华医学杂志,2014,94(38):3011-3013. [12] 李燕,王晓敏,毛敏,等.小剂量利妥昔单抗治疗复发难治性原发免疫性血小板减少症的临床观察[J].中华血液学杂志,2012,33(3):204-206. [13] 唐世锋,杜忠海.中医药治疗原发性血小板减少性紫癜的临床研究进展[J].河北中医,2013,35(3):467-470. [14] 王新波.特发性血小板减少性紫癜中医病名探析[J].中医杂志,2012,53(1):75-77. [15] 黄景清,张小群,严鲁萍,等.严鲁萍教授运用中医药辨证治疗特发性血小板减少性紫癜的经验[J].中医临床研究,2014,(5):79-80. [16] 张姗姗,郑春梅,肖海燕,等.益气养阴活血法配合西药治疗成人慢性特发性血小板减少性紫癜疗效观察[J].陕西中医,2012,33(1):50-51. [17] 周韶虹,陈英坤.免疫性血小板减少症的中医辨治浅探[J].中医临床研究,2012,04(5):114-115. [18] 刘晓帆,薛峰,张磊,等.血小板膜糖蛋白特异性抗体在原发免疫性血小板减少症患者中的分布及与疗效的关系[J].中华血液学杂志,2013,34(7):610-613. [19] 王娜,柴忆欢,何海龙,等.特发性血小板减少性紫癜患儿血小板膜糖蛋白表达及临床意义[J].中华实用儿科临床杂志,2013,28(3):210-213. [20] 鲍静,倪合宇,夏瑞祥,等.血小板特异性自身抗体和淋巴细胞亚群检测在免疫性血小板减少症中的临床价值[J].安徽医科大学学报,2012,47(6):691-694.
2016, Vol. 33 
